Announcements

FNIH Statement on the Moderate Alcohol and Cardiovascular Health Trial Follow-Up Report

December 13, 2018  Today, the National Institutes of Health (NIH) Advisory Committee to the Director (ACD) issued a follow-up report on the Moderate Alcohol and Cardiovascular Health Trial (MACH). The following is the FNIH’s statement on the report. 

Read More

The FNIH Supports the NIH Position on Claim of First Gene-Edited Babies by Chinese Researcher

November 29, 2018  The FNIH supports the NIH's position on the claim of the first gene-edited babies by a Chinese researcher. 

Read More

Foundation for the NIH and Jayne Koskinas Ted Giovanis Foundation for Health and Policy Renew Support for Training Two Research Fellows at the NIH

November 8, 2018  The Foundation for the National Institutes of Health (FNIH) and Jayne Koskinas Ted Giovanis (JKTG) Foundation for Health and Policy are proud to announce renewed support for the intramural research training of two young fellows at the National Institutes of Health (NIH). The fellowships are being made possible by a generous donation from the JKTG Foundation for Health and Policy to the FNIH.

Read More

NIH, Amgen Foundation, and FNIH Renew Support for Undergraduate Research Opportunities

November 7, 2018  A program at the National Institutes of Health to provide hands-on laboratory experience to undergraduate students from across the United States will continue for another four years, thanks to a grant from the Amgen Foundation to the Foundation for the National Institutes of Health (FNIH). The Amgen Scholars Program at NIH aims to break down barriers for many students who otherwise would not have the opportunity to engage in science at the world’s top educational and research institutions. Financial support for students is a critical component of the program, which seeks to ensure that eligible students, regardless of their financial status, can participate. The program is made possible by a grant from the Amgen Foundation to the FNIH.

Read More

Q&A with George H. Talbot, M.D.: Improving Antibacterial Drug Development Tools

October 2, 2018 — Bacterial infections acquired in hospitals are a major concern for healthcare providers and their patients. In particular, hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) are severe infections that cause patient deaths. As bacterial resistance to antibiotics increases, new treatments to combat these infections are desperately needed. Yet, measuring the effectiveness of new treatments continues to be a challenge due to a lack of well-defined clinical trial endpoints (outcomes measured to determine whether a therapy being studied is beneficial to patients).

Read More

The Role of Public-Private Partnerships in the Cancer Moonshot: How PACT can Transform Cancer Immunotherapy Clinical Trials

September 21, 2018 - Today, Vice President Joe Biden and Dr. Jill Biden are hosting the national Biden Cancer Summit in Washington, D.C. This event is one of more than 350 Biden Cancer Community Summits convening across the country to bring together patients and caregivers with the scientific community to help promote new solutions for tackling cancer and share stories of the tremendous resilience and strength shown by those who have been touched by the disease and remain #CancerFIERCE. 

Read More

FNIH Biomarkers Consortium Launches Project Seeking Regulatory Qualification of Biomarkers for Measuring Knee Osteoarthritis

August 2, 2018 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has launched a project, under its Inflammation and Immunity Steering Committee, to seek regulatory qualification of new biological markers (biomarkers) that predict the change in joint damage over time from osteoarthritis (OA) in the knee. The PROGRESS OA: Clinical Evaluation and Qualification of Osteoarthritis Biomarkers project, managed by the FNIH, will submit a comprehensive report, including imaging (i.e., MRI) and biochemical (i.e., urine, serum) biomarkers, for review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA). Biomarker qualification is the result of a formal regulatory process that affirms a biomarker can be relied upon to have a specific interpretation and used in the review of a potential drug. The acceptance of these biomarkers for use in drug development will pave the way for improved clinical trials and treatments for knee OA.

Read More

FNIH Statement on the Moderate Alcohol and Cardiovascular Health Trial Working Group Report

June 15, 2018 — Today, the Moderate Alcohol and Cardiovascular Health Trial (MACH) Working Group presented a report to the National Institutes of Health (NIH) Advisory Committee to the Director. The following is the FNIH’s response to the report.

Read More

The FNIH Earns the Highest Rating from Charity Navigator

June 12, 2018 — The Foundation for the National Institutes of Health (FNIH) has received top honors again this year from Charity Navigator by earning its coveted 4-star rating. The nation’s largest charity evaluator has recognized the FNIH with its highest rating for demonstrating strong financial health and commitment to accountability and transparency. Only 13 percent of the charities evaluated by Charity Navigator have received at least four consecutive, 4-stars, indicating the FNIH “outperforms most charities in America.”

Read More

American Journal of Tropical Medicine and Hygiene Publishes Recommendations for Safe and Ethical Testing of Gene Drive Mosquitoes to Reduce Malaria Transmission in Africa

June 7, 2018 — The American Journal of Tropical Medicine and Hygiene (AJTMH) has published an article outlining recommendations for the safe and ethical testing of gene drive technology on mosquitoes to reduce the burden of malaria transmission in Africa.

Read More